journal article·2022-04Open access

Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines

Romina Mitarotonda, Exequiel Giorgi, Tatiane Eufrasio-da-Silva, Alireza Dolatshahi-Pirouz, Yogendra Kumar Mishra, Ali Khademhosseini, Martin F. Desimone, Mauricio De Marzi, Gorka Orive

Abstract

The development of nanoparticles (NPs) with potential therapeutic uses represents an area of vast interest in the scientific community during the last years. Recently, the pandemic caused by COVID-19 motivated a race for vaccines creation to overcome the crisis generated. This is a good demonstration that nanotechnology will most likely be the basis of future immunotherapy. Moreover, the number of publications based on nanosystems has significantly increased in recent years and it is expected that most of these developments can go on to experimentation in clinical stages soon. The therapeutic use of NPs to combat different diseases such as cancer, allergies or autoimmune diseases will depend on their characteristics, their targets, and the transported molecules. This review presents an in-depth analysis of recent advances that have been developed in order to obtain novel nanoparticulate based tools for the treatment of allergies, autoimmune diseases and for their use in vaccines. Moreover, it is highlighted that by providing targeted delivery an increase in the potential of vaccines to induce an immune response is expected in the future. Definitively, the here gathered analysis is a good demonstration that nanotechnology will be the basis of future immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Inhalation and Respiratory Drug Delivery · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Innate immunity: impact on the adaptive immune response10.1016/S0952-7915(97)80152-5 ↗
2. The immune system10.1042/EBC20160017 ↗
3. Evolution of innate and adaptive immunity: can we draw a line?10.1016/j.it.2004.10.001 ↗
4. Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy10.1021/acsami.8b22693 ↗
5. Ligand-switchable micellar nanocarriers for prolonging circulation time and enhancing targeting efficiency10.1021/acsami.7b18137 ↗
6. Dual-functionalized janus mesoporous silica nanoparticles with active targeting and charge reversal for synergistic tumor-targeting therapy10.1021/acsami.9b15434 ↗
7. Review of emerging nanotechnology in bone regeneration: progress, challenges, and perspectives10.1039/D1NR01371H ↗
8. Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy10.1021/acsami.6b10175 ↗
9. Modularly assembled upconversion nanoparticles for orthogonally controlled cell imaging and drug delivery10.1021/acsami.0c00672 ↗
10. Engineering precision nanoparticles for drug delivery
11. Quantum dots in biomedical applications10.1016/j.actbio.2019.05.022 ↗
12. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy10.1002/smll.202006484 ↗
13. Biomedical nanomaterials for immunological applications: ongoing research and clinical trials10.1039/D0NA00478B ↗
14. Evolution and clinical translation of drug delivery nanomaterials10.1016/j.nantod.2017.06.008 ↗
15. Effect of micro- and nanoparticle shape on biological processes
16. Cross-species comparisons of nanoparticle interactions with innate immune systems: a methodological review10.3390/nano11061528 ↗
17. Modulation of immune response using engineered nanoparticle surfaces10.1002/smll.201502273 ↗
18. Potential of nanoparticles for allergen-specific immunotherapy–use of silica nanoparticles as vaccination platform10.1080/17425247.2016.1203898 ↗
19. The new era of nanotechnology, an alternative to change cancer treatment10.2147/DDDT.S142337 ↗
20. Potential applications of nanoparticles in cancer immunotherapy10.1080/21645515.2016.1245251 ↗
21. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer10.1016/j.nano.2019.102034 ↗
22. The immunomodulatory effects of titanium dioxide and silver nanoparticles10.1016/j.fct.2015.05.015 ↗
23. Use of nanoparticles to deliver immunomodulatory oligonucleotides10.1002/wnan.1382 ↗
24. Immunomodulatory effects of nanoparticles on skin allergy10.1038/s41598-017-03729-2 ↗
25. Addressing nanomaterial immunosafety by evaluating innate immunity across living species10.1002/smll.202000598 ↗
26. Nanotechnology for hepatocellular carcinoma: from surveillance, diagnosis to management
27. Current stimuli-responsive mesoporous silica nanoparticles for cancer therapy10.3390/pharmaceutics13010071 ↗
28. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection10.1016/j.addr.2020.12.006 ↗
29. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering10.1021/acs.nanolett.9b04246 ↗
30. Nanoparticles for immune cytokine TRAIL-based cancer therapy10.1021/acsnano.7b05876 ↗
31. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy10.1021/acs.nanolett.6b03329 ↗
32. Mannose-functionalized biodegradable nanoparticles efficiently deliver DNA vaccine and promote anti-tumor immunity10.1021/acsami.1c01401 ↗
33. Prodrug-based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death10.1002/smll.202000214 ↗
34. Immune checkpoint blockade mediated by a small-molecule nanoinhibitor targeting the PD-1/PD-L1 pathway synergizes with photodynamic therapy to elicit antitumor immunity and antimetastatic effects on breast cancer10.1002/smll.201903881 ↗
35. Boosting Interleukin-12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR-tagged nanogold10.1002/smll.201903462 ↗
36. Local immunomodulation using an adhesive hydrogel loaded with miRNA-laden nanoparticles promotes wound healing10.1002/smll.201902232 ↗
37. Nanoparticle-based nanomedicines to promote cancer immunotherapy: recent advances and future directions
38. Tumor microenvironment-triggered in-situ cancer vaccines with dual immunogenic cell death inductions for elevated antitumor and antimetastatic therapy
39. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages10.1039/D0NR08050K ↗
40. Engineering immunological tolerance using quantum dots to tune the density of self-antigen display10.1002/adfm.201700290 ↗
41. Self-assembly as a molecular strategy to improve immunotherapy10.1021/acs.accounts.0c00438 ↗
42. Effects of engineered nanoparticles on the innate immune system10.1016/j.smim.2017.09.011 ↗
43. Immunological properties of engineered nanomaterials10.1038/nnano.2007.223 ↗
44. Fullerene nanomaterials inhibit the allergic response10.4049/jimmunol.179.1.665 ↗
45. Induction of humoral immune response against PfMSP-119 and PvMSP-119using gold nanoparticles along with alum10.1016/j.vaccine.2011.01.014 ↗
46. Gold nanoparticles (AuNPs) impair LPS-driven immune responses by promoting a tolerogenic-like dendritic cell phenotype with altered endosomal structures10.1039/D0NR09153G ↗
47. Immunomodulation of nanoparticles in nanomedicine applications
48. Differential regulation of macrophage inflammatory activation by fibrin and fibrinogen10.1016/j.actbio.2016.09.024 ↗
49. Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties10.2147/IJN.S215941 ↗
50. Systematic evaluation of transferrin-modified porous silicon nanoparticles for targeted delivery of doxorubicin to glioblastoma10.1021/acsami.9b10787 ↗
51. Use of polymeric nanoparticle platform targeting the liver to induce treg-mediated antigen-specific immune tolerance in a pulmonary allergen sensitization model10.1021/acsnano.9b01444 ↗
52. Novel coronavirus-like particles targeting cells lining the respiratory tract10.1371/journal.pone.0203489 ↗
53. Nano and Microparticle emerging strategies for treatment of autoimmune diseases: multiple sclerosis and type 1 diabetes10.1002/adhm.202000164 ↗
54. Targeted immunomodulation using antigen-conjugated nanoparticles10.1002/wnan.1263 ↗
55. Harnessing nanoparticles for immune modulation10.1016/j.it.2015.05.007 ↗
56. Nanoparticle-based autoimmune disease therapy10.1016/j.clim.2015.02.003 ↗
57. Nanoparticles and direct immunosuppression10.1177/1535370216650053 ↗
58. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction, nanomedicine nanotechnology
59. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes10.1093/toxsci/kfm196 ↗
60. Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce site-specific Th2 inflammatory responses via the IL-33/ST2 axis
61. Signaling pathways implicated in carbon nanotube-induced lung inflammation10.3389/fimmu.2020.552613 ↗
62. Direct effects of carbon nanotubes on dendritic cells
63. The suppressive effect of il-27 on encephalitogenic th17 cells induced by multiwalled carbon nanotubes reduces the severity of experimental autoimmune encephalomyelitis10.1111/cns.12121 ↗
64. Hydroxylated fullerenes inhibit neutrophil function in fathead minnow (Pimephales promelas rafinesque
65. Water-soluble fullerene (c60) inhibits the development of arthritis in the rat model of arthritis10.2147/IJN.S7653 ↗
66. Graphene quantum dots inhibit T cell-mediated neuroinflammation in rats10.1016/j.neuropharm.2018.11.030 ↗
67. Graphene oxide polarizes iNKT cells for production of TGFβ and attenuates inflammation in an iNKT cell-mediated sepsis model10.1038/s41598-018-28396-9 ↗
68. Improved biocompatibility of amino-functionalized graphene oxide in Caenorhabditis elegans10.1002/smll.201902699 ↗
69. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant10.1016/j.actbio.2020.06.009 ↗
70. Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation10.4049/jimmunol.1100156 ↗
71. Biodegradable nanocarriers resembling extracellular vesicles deliver genetic material with the highest efficiency to various cell types10.1002/smll.201904880 ↗
72. Carboxyl- and amino-functionalized polystyrene nanoparticles differentially affect the polarization profile of M1 and M2 macrophage subsets10.1016/j.biomaterials.2016.01.064 ↗
73. Results of a 30-day safety assessment in young mice orally exposed to polystyrene nanoparticles10.1016/j.envpol.2021.118184 ↗
74. Physiologic control of the functional status of Foxp3+ regulatory T cells10.4049/jimmunol.1002937 ↗
75. Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells10.4049/jimmunol.1103668 ↗
76. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses10.4049/jimmunol.1301419 ↗
77. Activation of the STING adaptor attenuates experimental autoimmune encephalitis10.4049/jimmunol.1303258 ↗
78. STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?10.1586/1744666X.2015.995097 ↗
79. Template-mediated assembly of DNA into microcapsules for immunological modulation10.1002/smll.202002750 ↗
80. Modulating immune response with nucleic acid nanoparticles10.3390/molecules24203740 ↗
81. Gold nanoparticles downregulate interleukin-1β-induced pro-inflammatory responses10.1002/smll.201201528 ↗
82. Effect of gold nanoparticles in the treatment of established collagen arthritis in rats
83. Gold nanoparticles modulate BCG-induced innate immune memory in human monocytes by shifting the memory response towards tolerance10.3390/cells9020284 ↗
84. Anti-inflammatory properties of cerium oxide nanoparticles10.1002/smll.200901048 ↗
85. Immunomodulation and T helper TH1/TH2Response polarization by CeO2and TiO2Nanoparticles10.1371/journal.pone.0062816 ↗
86. Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity10.1016/j.expneurol.2015.08.008 ↗
87. Protective effects of nanoceria in imiquimod induced psoriasis by inhibiting the inflammatory responses10.2217/nnm-2018-0515 ↗
88. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death10.1016/j.chembiol.2005.09.008 ↗
89. Cadmium telluride quantum dot nanoparticle cytotoxicity and effects on model immune responses to Pseudomonas aeruginosa10.3109/17435390.2011.648667 ↗
90. Graphene quantum dots as anti-inflammatory therapy for colitis
91. Nanocrystal quantum dots in vitro and in vivo, 5210.1109/TNB.2009.2016550 ↗
92. Size distribution effects of cadmium tellurium quantum dots (CdS/CdTe) immunotoxicity on aquatic organisms10.1039/c2em30896g ↗
93. Toxicity of quantum dots on target organs and immune system10.1002/jat.4180 ↗
94. Ti-O based nanomaterials ameliorate experimental autoimmune 2 encephalomyelitis and collagen-induced arthritis10.1039/C5RA18974H ↗
95. Foodborne titanium dioxide nanoparticles induce stronger adverse effects in obese mice than non-obese mice: gut microbiota dysbiosis, colonic inflammation, and proteome alterations
96. Impacts of foodborne inorganic nanoparticles on the gut microbiota-immune axis: potential consequences for host health10.1186/s12989-020-00349-z ↗
97. Nanoengineered silica: properties, applications and toxicity10.1016/j.fct.2017.05.054 ↗
98. Recent patents on the synthesis and application of silica nanoparticles for drug delivery10.2174/187220811795655887 ↗
99. A collagen-silica-based biocomposite for potential application in bone tissue engineering10.1002/jbm.a.37291 ↗
100. Development of pH-responsive biopolymer-silica composites loaded with Larrea divaricata cav. Extract with antioxidant activity10.1016/j.colsurfb.2018.05.015 ↗